{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:15:23Z","timestamp":1792401323916,"version":"4.4.0"},"reference-count":33,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2013,10,28]],"date-time":"2013-10-28T00:00:00Z","timestamp":1382918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Since dermatomyositis (DM) is associated with an increased risk of malignancy, accurate identification of patients likely to harbor cancers is important. Using immunoprecipitations from radiolabeled cell lysates, several groups recently showed that anti\u2013transcription intermediary factor 1\u03b3 (anti\u2013TIF\u20101\u03b3) antibodies are associated with malignancy in DM. We undertook this study to develop sensitive, specific assays to detect antibodies against TIF\u20101\u03b3 and nuclear matrix protein NXP\u20102 and to evaluate their association with malignancy in DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To detect anti\u2013TIF\u20101\u03b3 antibodies, immunoprecipitations were performed using lysates made from HeLa cells overexpressing TIF\u20101\u03b3, with detection by immunoblotting. Anti\u2013NXP\u20102 antibodies were assayed by immunoprecipitation using <jats:sup>35<\/jats:sup>S\u2010methionine\u2013labeled NXP\u20102 generated by in vitro transcription\/translation. We analyzed patient sera from DM cohorts seen at the Stanford University Dermatology Clinic (n = 111) and the Johns Hopkins Myositis Center (n = 102).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 17% and 38% of patients had antibodies against NXP\u20102 and TIF\u20101\u03b3, respectively. Reactivity against either NXP\u20102 or TIF\u20101\u03b3 identified 83% of patients with cancer\u2010associated DM. In addition to older age and male sex, cancer was associated with antibodies to NXP\u20102 or TIF\u20101\u03b3 on multivariate analysis (odds ratio 3.78 [95% confidence interval 1.33\u201310.8]). Stratification by sex revealed that anti\u2013NXP\u20102 was specifically associated with cancer in males (odds ratio 5.78 [95% confidence interval 1.35\u201324.7]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These studies demonstrate that anti\u2013NXP\u20102 and anti\u2013TIF\u20101\u03b3 antibodies are frequent DM specificities (found in 55% of patients) and are present in most patients with cancer\u2010associated DM.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.38093","type":"journal-article","created":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T14:13:44Z","timestamp":1378217624000},"page":"2954-2962","source":"Crossref","is-referenced-by-count":382,"title":["Most Patients With Cancer\u2010Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP\u20102 or Transcription Intermediary Factor 1\u03b3"],"prefix":"10.1002","volume":"65","author":[{"given":"David F.","family":"Fiorentino","sequence":"first","affiliation":[{"name":"Stanford University School of Medicine Stanford California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorinda S.","family":"Chung","sequence":"additional","affiliation":[{"name":"VA Palo Alto Health Care System Palo Alto California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christopher\u2010Stine","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zaba","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine Stanford California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Li","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine Stanford California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Rosen","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Casciola\u2010Rosen","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,10,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3275"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328358bd85"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03216.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33403"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24547"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep375"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24621"},{"key":"e_1_2_7_9_1","first-page":"S518","article-title":"Autoantibodies to transcriptional intermediary factor 1\u2010gamma (TIF1\u2010g) in dermatomyositis","volume":"54","author":"Targoff IN","year":"2006","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_10_1","first-page":"S787","article-title":"Sera with autoantibodies to the MJ antigen react with NXP2","volume":"56","author":"Targoff IN","year":"2007","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2323-y"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.016"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.52"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq153"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21023"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21992"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33379"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01262.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-11-223"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068502"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22164"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem359"},{"key":"e_1_2_7_23_1","first-page":"S304","article-title":"Autoantibodies to the p140 autoantigen NXP\u20102 in adult dermatomyositis","volume":"60","author":"Betteridge ZE","year":"2009","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3822"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200697"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes033"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090461"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(02)00021-9"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000173991.74008.b0"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.041"},{"key":"e_1_2_7_32_1","first-page":"S85","article-title":"Anti\u2010MJ\/NXP\u20102 antibodies are the most common specificity in a cohort of adult Caucasian patients with dermatomyositis","volume":"63","author":"Ceribelli A","year":"2011","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781444300161.ch56"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.328"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.38093","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.38093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T06:08:41Z","timestamp":1698646121000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.38093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,28]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1002\/art.38093"],"URL":"https:\/\/doi.org\/10.1002\/art.38093","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,28]]}}}